find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT02343042 / KCP-330-017
A Phase 1b/2 Study Of Selinexor (KPT-330) In Combination With Backbone Treatments For Relapsed/Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase II
Accepting Patients
nct/study# NCT04661137 / KARYOPHARM-IST-318-2020-0369
A Phase 2B Study Of Selinexor (KPT-330), In Combination With Carfilzomib, Daratumumab Or Pomalidomide In Patients With Multiple Myeloma Relapsing On Current Therapy
Learn More
Multiple Myeloma
NA
Accepting Patients
nct/study# NA / CCSG-PILOT-PROJECT
Exploring The Clinical Relevance Of Matriptase Expression In Multiple Myeloma
Learn More
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT03314181 / M15-654
A Phase 1/2, Multicenter, Dose-Escalation And Expansion Study Of Combination Therapy With Venetoclax, Daratumumab And Dexamethasone (With And Without Bortezomib) In Subjects With Relapsed Or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
N/A
Accepting Patients
nct/study# NCT04150289 / RECOMM
A Disease Registry Encompassing The Care Of Patients With Multiple Myeloma On Panobinostat (RECOMM)
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04196491 / BB-2121-MM-004
A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.